Sabet Amir, Binse Ina, Dogan Semih, Koch Andrea, Rosenbaum-Krumme Sandra J, Biersack Hans-Jürgen, Biermann Kim, Ezziddin Samer
Department of Nuclear Medicine, University Duisburg-Essen, Essen, Germany.
Department of Nuclear Medicine, Saarland University Hospital, Kirrbergerstr., Geb. 50, D-66421, Homburg, Germany.
Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):190-195. doi: 10.1007/s00259-016-3485-3. Epub 2016 Aug 16.
Distant metastasis has a negative impact on survival in differentiated thyroid carcinoma (DTC). The timing of this manifestation, however, is of unknown prognostic relevance. The aim of this retrospective study was to investigate the potential significance of discriminating synchronous versus metachronous distant metastases (SDM vs. MDM) for the outcome of patients with DTC.
We retrospectively analyzed a consecutive cohort of n = 89 patients with distant metastases of DTC (43 with follicular, 46 with papillary DTC histology; mean age 52.6 ± 17.7 years) undergoing radioiodine treatment at our institution. All patients were treated with the same protocol consisting of ablative radioiodine therapy (RIT, 3.7 GBq) and one post-ablation treatment after 3 months (3.7-11.1 GBq). Further cycles of RIT were administered for recurrent, progressive or newly developed metastatic disease. We distinguished 2 types of distant metastases according to the time of manifestation: SDM (within ≤12 months after DTC diagnosis) and MDM (occurring >12 months after diagnosis). Tumor-related survival was analyzed using the Kaplan-Meier method. Uni- and multivariate analyses including the Cox proportional hazards model were performed with a significance level of p < 0.05.
The mean follow-up period was 13.8 ± 1.2 years. SDM were present in 49 (55.1 %), MDM in 40 (44.9 %) patients. MDM were associated with shorter tumor-related survival (p = 0.002). 5-year and 10-year survival rates were 68.5 % and 34.8 % for MDM, and 84.3 % and 66.9 % for SDM, respectively. Within both age subgroups of <45 and ≥45 years, SDM were also linked with longer survival. No effect on tumor-related survival was found for the co-variables sex, lymph node metastases and histologic type.
Distinguishing synchronous from metachronous manifestation of distant metastases may add an important prognostic feature to risk stratification in DTC, as proven metachronous appearance is associated with impaired survival.
远处转移对分化型甲状腺癌(DTC)的生存有负面影响。然而,这种表现出现的时间与预后的相关性尚不清楚。本回顾性研究的目的是探讨区分同步性与异时性远处转移(SDM与MDM)对DTC患者预后的潜在意义。
我们回顾性分析了我院连续收治的89例发生远处转移的DTC患者(43例滤泡状、46例乳头状DTC组织学类型;平均年龄52.6±17.7岁),这些患者均接受了放射性碘治疗。所有患者均采用相同的方案治疗,包括消融性放射性碘治疗(RIT,3.7GBq)及3个月后进行的一次消融后治疗(3.7 - 11.1GBq)。对于复发、进展或新出现的转移性疾病,给予进一步的RIT周期治疗。根据转移出现的时间,我们区分了2种远处转移类型:SDM(在DTC诊断后≤12个月内)和MDM(在诊断后>12个月出现)。采用Kaplan - Meier法分析肿瘤相关生存率。进行单因素和多因素分析,包括Cox比例风险模型,显著性水平设定为p < 0.05。
平均随访期为13.8±1.2年。49例(55.1%)患者出现SDM,40例(44.9%)患者出现MDM。MDM与较短的肿瘤相关生存期相关(p = 0.002)。MDM的5年和10年生存率分别为68.5%和34.8%,SDM分别为84.3%和66.9%。在年龄<45岁和≥45岁的两个亚组中,SDM也与更长的生存期相关。未发现性别、淋巴结转移和组织学类型等协变量对肿瘤相关生存期有影响。
区分远处转移的同步性与异时性表现可能为DTC的风险分层增加一个重要的预后特征,因为已证实异时性出现与生存期受损相关。